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Abstract
Cancer cells secrete procathepsin D, and its secretion is enhanced by estradiol. Although
alterations in the pro-enzyme intracellular transport have been reported, the mechanism by
which it is secreted remains poorly understood. In this work, we have studied the influence
of estradiol on the expression and distribution of the cation-dependent mannose-6-phos-
phate receptor (CD-MPR), which would be a key molecule to ensure the proper localization
of the enzyme to lysosomes in breast cancer cells. Immunoblotting studies demonstrated
that the expression of CD-MPR is higher in MCF-7 cells, as compared to other breast cancer
and non-tumorigenic cells. This expression correlated with high levels of cathepsin D (CatD)
in these cells. By immunofluorescence, this receptor mostly co-localized with a Golgi marker
in all cell types, exhibiting an additional peripheral labelling in MCF-7 cells. In addition, CD-
MPR showed great differences regarding to cation-independent mannose-6-phosphate
receptor. On the other hand, the treatment with estradiol induced an increase in CD-MPR
and CatD expression and a re-distribution of both proteins towards the cell periphery. These
effects were blocked by the anti-estrogen tamoxifen. Moreover, a re-distribution of CD-MPR
to plasma membrane-enriched fractions, analyzed by gradient centrifugation, was observed
after estradiol treatment. We conclude that, in hormone-responsive breast cancer cells, CD-
MPR and CatD are distributed together, and that their expression and distribution are influ-
enced by estradiol. These findings strongly support the involvement of the CD-MPR in the
pro-enzyme transport in MCF-7 cells, suggesting the participation of this receptor in the pro-
cathepsin D secretion previously reported in breast cancer cells.
Introduction
Cathepsin D (CatD) is a soluble aspartic protease that is overexpressed and secreted in high
amounts by breast cancer cells [1, 2]. In primary breast carcinomas, the expression of this
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protein correlates with tumor progression and metastasis, therefore, it has been proposed as a
marker of poor prognosis [3]. CatD is secreted as a pro-enzyme (proCatD), which can act as a
mitogen on cancer and stromal cells, stimulating their pro-invasive and pro-metastatic capaci-
ties [4]. The CatD gene is controlled by a mixed promoter, which has both house-keeping and
regulated gene features [5]. In this context, it has been well documented that, in hormone-
responsive breast cancer cells, the transcription of CatD is induced by estradiol [6, 7]. In fact,
the majority of cancer cell lines secrete over 50% of their proCatD production [2], being this
secretion enhanced by estradiol [8].
In mammalian cells, under physiological conditions, most of CatD is confined to lysosomes
and only between 5–10% of the precursor molecules are secreted [9]. CatD is synthesized in
the rough endoplasmic reticulum as a pre-pro-enzyme and, after the removal of its signal pep-
tide to generate proCatD, the molecule is glycosylated at two N-linked glycosylation sites to be
transported to the Golgi apparatus. In the cis-Golgi network, proCatD is specifically modified
by the addition of mannose 6-phosphate (M6P) residues to be targeted by mannose-6-phos-
phate receptors (MPRs) to lysosomes [10]. To be active, the pro-enzyme has to be processed to
its mature form. This process begins in the late endosomes where the acidic pH favors the
cleavage of proCatD (52 kDa) to render a single chain form ( 48 kDa), which reaches the
lysosomes and is further processed to the mature two-chain form, i.e., CatD ( 33 and 14
kDa) [11].
Targeting of newly synthesized acid hydrolases by sortilin and LIMP-2 has also been pro-
posed [12, 13]. Nonetheless, the M6P recognition pathway remains a key step in lysosomal tar-
geting [14, 15]. Mammalian cells have two distinct MPRs: the 46 kDa cation-dependent MPR
(CD-MPR) and the 300 kDa cation-independent MPR (CI-MPR). The biological significance
of the existence of two MPRs with comparable function is still unclear. Both MPRs recognize
M6P bearing ligands at the trans-Golgi network (TGN). Once recognized, these ligands are
transported to an acidified pre-lysosomal compartment where the low pH causes the enzyme-
receptor complex to dissociate. Consequently, the lysosomal enzymes are delivered to the lyso-
somes, while the receptors recycle back to the Golgi stacks [16]. Additionally, MPRs can also
reach the cell surface [17] by several possible mechanisms, i.e., a missorting occurring at the
TGN, through transport carriers derived from C5/6 stacks; and/or through recycling routes
from either early [18] or late endosomes [19]. Although both receptors are present on the cell
surface, only the CI-MPR can bind and internalize extracellular lysosomal enzymes and/or
non-phosphorylated ligands such as insulin-like growth factor 2 (IGF2), meanwhile the
CD-MPR has been proposed to mediate the secretion of hydrolase precursors [20].
The mechanism by which breast cancer cells secrete CatD is still poorly understood,
although some hypotheses have been proposed. The increased expression of CatD together
with a CI-MPR down regulation induced by estradiol [21], or a poor functionality of the recep-
tor [22], would contribute to the enzyme secretion by a rapid receptor saturation mechanism.
As for CD-MPR in tumor cells, little has been studied. Some authors have proposed that the
contribution of the CD-MPR to the targeting of newly synthesized lysosomal enzymes
becomes crucial only if the functionality of CI-MPR is deficient in non-tumorigenic cells. In
that case, a fraction of the pro-enzymes that bind to the CD-MPR are secreted [20]. Given that
intracellular transport alterations have been proposed to explain the exacerbated proCatD
secretion by breast cancer cells and that CD-MPR has been scarcely studied in these cell types,
in this work, we have studied the expression and distribution of CD-MPR in comparison with
CI-MPR in a model of hormone-responsive breast ductal adenocarcinoma cell line, and
attempted to correlate it with the expression and distribution of CatD, under basal conditions
and under estradiol stimulation. The behaviour of the CD-MPR and its response to the
CD-MPR and estradiol in MCF-7 cells
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hormone could be correlated with the exacerbated secretion of the pro-enzyme, a phenome-
non that has been reported by other authors [1, 23].
Materials and methods
Antibodies and reagents
The goat anti-CatD antiserum was purchased from Santa Cruz Biotechnology (sc-6487 Dallas,
TX, USA), and used 1:1000 in PBS for immunoblotting (IB) and 1:150 for immunofluores-
cence (IFI). The rabbit anti-CD-MPR antiserum was gently provided by Dr. Luzio (Cambridge
University, UK), and used 1:250 for IB and 1:200 for IFI. The rabbit anti-CI-MPR antiserum
was gently provided by Dr. Nancy Dahms (Medical College of Wisconsin, USA) and used 1:
500 for IB and 1:100 for IFI. The rabbit anti-LAMP1 antiserum (ab-24170) and mouse anti-β-
tubulin monoclonal antibody (ab-56676) were obtained from Abcam (USA). The mouse anti-
golgin97 monoclonal antibody was obtained from Santa Cruz Biotechnology (sc-73619). The
HRP-conjugated anti-goat IgG antiserum was obtained from H&L (401515), the HRP-conju-
gated anti-rabbit IgG fraction was obtained from Sigma (A9169) and the HRP-conjugated
anti-mouse IgG (whole molecule) was purchased from Sigma (A9044). Chemiluminescent
reagents were from Pearce (Rockford, IL, USA).
Cell cultures
Three breast cell lines were used in this study; the non-tumorigenic MCF-10A, and the tumor-
igenic, MCF-7 and MDA-MB-231 cell lines, obtained from the American Type Culture Collec-
tion (ATCC, Rockville, MD, USA). The MCF-10A is a human-derived mammary epithelial
cell line which does not express estrogen receptor alpha (ERα), and whose characteristics are
those of the normal breast epithelial cells [24]. The MCF-7 is a hormone-sensitive breast ductal
adenocarcinoma-derived cell line expressing ERα. The MDA-MB-231 is also a breast ductal
adenocarcinoma-derived cell line, but it presents a phenotype that is more mesenchymal than
epithelial, and molecularly classified as triple negative (ER-/PR-/HER2-). All cell lines were
used with 10–15 passages.
MCF-7 and MDA-MB-231 cell lines were cultured in DMEM Base (Sigma) supplemented
with 10% charcolized fetal bovine serum (Internegocios), 2 mM L-glutamine (Sigma), 44 mM
sodium bicarbonate, 1 mM sodium pyruvate, 5.6 mM glucose, 50 IU/50 μg/ml penicillin-strep-
tomycin (Gibco) at 37˚C under a 5% CO2 atmosphere.
The MCF-10A cell line was cultured in DMEM F12 HAM (Sigma), supplemented with 10%
charcolized fetal bovine serum, 2 mM L-glutamine, 10 μg/ml insulin (Sigma), 10 ng/ml EGF
(Sigma), 0.5 μg/ml hydrocortisone (Sigma), and 50 IU/50 μg/ml penicillin-streptomycin.
Hormone treatments
MCF-7 and MCF-10A cells (60% confluence) were cultured as described above in T25 flasks
with the corresponding culture media in the absence or in the presence of either 20 nM estra-
diol (Sigma) or 20 nM estradiol plus 2 μM tamoxifen (Sigma), for 12, 24 or 48 h. After incuba-
tion, cells were harvested after treatment with 0.1% trypsin (Gibco) for 5 min and processed
for immunoblotting.
Immunoblotting analysis
Cells were lysed with lysis buffer (PBS containing 1% Nonidet P-40 and 1mM PMSF), and
homogenized by cellular disruption with a 0.5 mm needle followed by sonication. Proteins
(40 μg) from the homogenates from each sample were resuspended in Laemmli’s buffer [25],
CD-MPR and estradiol in MCF-7 cells
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and boiled for 5 min. For CI-MPR detection, homogenate proteins were resuspended in the
Laemmli’s buffer without SDS and not boiled. Proteins were analyzed by electrophoresis in
6–10% polyacrylamide gels. The immunoblotting was carried out following the protocol of
Romano et al. [26]. Briefly, after electrophoresis, proteins were electrotransferred onto nitro-
cellulose membranes (GE Healthcare, Amersham, Germany), for 4 h at 250 mA for detection
of CI-MPR or for 1 h, at 250 mA for the other proteins under study. Membranes were blocked
with 5% skimmed milk in buffer A (0.2% Tween 20 in PBS) for 1 h and incubated with the cor-
responding primary antibodies overnight at 4˚C. After three washings with buffer A, mem-
branes were incubated with the corresponding HRP-conjugated secondary antibodies. Specific
bands were revealed by chemiluminescence and the signal was detected with a LAS 4000 imag-
ing system (Fujifilm Lifescience, USA). Band intensities were quantified by densitometry
using the Image J software (Image Processing and Analysis in Java; National Institutes of
Health, Bethesda, MD, USA).
Indirect immunofluorescence
Cells were grown on 1 cm diameter round coverslips seated at the bottom of culture wells
under the conditions described above. Once 50% confluence was reached, cells were washed
once with PBS and fixed with 3.7% paraformaldehyde for 20 min. Subsequently, cells were per-
meabilized with 0.1% saponin for 15 min, washed three times with PBS and blocked with 5%
horse serum for 30 min. Afterwards, cells were incubated with primary antibodies, at the dilu-
tion indicated above, overnight at 4˚C, then washed three times with PBS, and incubated with
the corresponding fluorochrome-conjugated secondary antibodies diluted in PBS-horse
serum for 90 min. Cell nuclei were stained with Hoescht, and coverslips were mounted on
slides with Mowiol mounting solution. Samples were analysed with an Olympus FV 1000 con-
focal microscope and images were acquired using the FV 10-ASW 1.7 software (Olympus,
Japan).
Quantitative co-localization analysis
The co-localization analysis was carried out with the JACoP plugin of the Image J software
(NIH [http://rsb.info.nih.gov/ij/plugins/track/jacop.html]). Pearson and Mander correlation
coefficients (PCC and MCC, respectively) were calculated. For PCC, the dependency of pixels
in dual-channel images (green/red channel for detection of CD-MPR/CatD; LAMP-1 /CatD
and CD-MPR/Golgin) was assessed by plotting the pixel grey values of two images against
each other. These values were displayed in a pixel-distribution diagram (scatter plot), and a lin-
ear equation describing the relationship between the intensities of the two images was deter-
mined by linear regression. A cross-correlation function (CCF) was obtained by plotting the
corresponding PCC for each pixel shift (δx) of the green image in the x direction relative to the
red image, or viceversa. The PCC value varied from 1 to -1, where values of 1 denote complete
correlation, while values of -1 suggest a negative correlation. Among the MCC coefficients, the
MCC-M1 and MCC-M2 were useful to describe the proportion of each protein that co-local-
ized with the other, since this coefficient is independent of the fluorophore fluorescence inten-
sity. The MCC values varied from 0 to 1, indicating no co-localization or complete co-
localization, respectively.
Discontinuous sucrose gradients
Subcellular fractions from MCF-7 cells subjected or not to hormone treatment, were obtained
in discontinuous sucrose gradients, according to other authors [27]. Briefly, MCF-7 cells were
harvested and homogenized with a teflon Dounce tissue homogenizer in buffer B (10 mM
CD-MPR and estradiol in MCF-7 cells
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Tris-HCl pH 7.4, containing 0.25 M sucrose, 1 mM EDTA, and 0.02% PMSF). Homogenates
were centrifuged at 3,000 g for 10 min and the resulting supernatants were then centrifuged at
30,000 g for 20 min. Pellets were then resuspended in buffer B, and the protein concentration
was determined according to Lowry [28]. Each membrane sample was loaded on top of a 20–
50% (w/w) discontinuous sucrose gradient (prepared in buffer C (10 mM Tris-HCl (pH 7.4),
containing 1 mM EDTA, 0.02% PMSF) and centrifuged at 100,000 g for 60 min at 4˚C. Frac-
tions of 1 mL were collected from the bottom and weighed to estimate the fraction density (W/
V). Subsequently, 2 ml of buffer C were added to each fraction, and centrifuged at 30,000 g for
30 min at 4˚C to remove sucrose. Final pellets were processed for immunoblotting.
Statistics
Data were analysed by the Tukey-Kramer multiple comparisons test. The level of significance
was set at p0.05. At least three independent experiments were performed in each case.
Results
Tumorigenic and non-tumorigenic breast cell lines express different levels
of CatD, CD-MPR and CI-MPR
The expression levels of the proteins under study were evaluated by immunoblotting. As
observed in Fig 1A, the mature form of CatD (33 kDa) is highly expressed in MCF-7 tumori-
genic cells and, at a lesser extent in non-tumorigenic (MCF-10A) and in tumorigenic triple
negative MDA-MB-231 cells. Moreover, the levels of the immature form of the enzyme (52
kDa) were also significantly higher in MCF-7 cells, indicating that the total expression of the
enzyme is increased in these cells. A similar trend was observed for the CD-MPR, since the
expression of this receptor was higher in the MCF-7 cells than in the MCF-10A or MDA-MB-
231 cells (Fig 1B). In contrast, the CI-MPR expression levels were significantly higher in MCF-
10A and MDA-MB-231 than in MCF-7 cells (Fig 1C).
The subcellular distributions of CatD and CD-MPR differ between
tumorigenic and non-tumorigenic breast cell lines
By IFI, a perinuclear location and a granular cytoplasmic distribution of CatD were observed
in the three breast cell lines. However, an additional peripheral punctuated distribution of the
Fig 1. Expression of CatD, CD-MPR and CI-MPR in non-tumorigenic and tumorigenic human breast cell lines.
MCF-10A, MCF-7 and MDA-MB-231 cell lysates were analyzed by immunoblotting. Representative immunoblottings
of CatD (A), CD-MPR (B) and CI-MPR (C) with their band intensity quantitation. ProCatD (52 kDa, upper panel)
and CatD (33 kDa, lower panel) were quantified separately. Bars represent the means of relative optical density (R.O.
D.) ± SEM from four independent experiments for each protein. () and () significant differences (p<0.01 and
p<0.05, respectively). Detection of β-tubulin and Ponceau red staining were used as loading control.
https://doi.org/10.1371/journal.pone.0201844.g001
CD-MPR and estradiol in MCF-7 cells
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enzyme, neighbouring the plasma membrane, was also observed in MCF-7 and MDA-MB-231
cell lines, but not in MCF-10A cells (Fig 2A, arrows). From these observations we evaluated
the degree of co-localization of the enzyme with the lysosomal associated membrane protein 1
(LAMP1) and compared it between MCF-7 and MCF-10A cells, since among these cells the
major difference in CatD distribution was observed. Although CatD showed partial co-locali-
zation with LAMP1 in MCF-7 and MCF-10A cell lines (Fig 2B), this co-localization was signif-
icantly lower in MCF-7 cells (Fig 2C), indicating the occurrence of higher location of the
enzyme in non-lysosomal/endosomal compartments, when compared to MCF-10A cells.
On the other hand, the CD-MPR localization was found to be mostly perinuclear in the
three cell lines (Fig 3A). Such location would correspond to the Golgi apparatus, as evidenced
by the simultaneous reactivity with golgin-97. However, in MCF-7 cells, an additional punctu-
ate CD-MPR labelling was observed dispersed in the cytoplasm. Such reactivity did not co-
localize with golgin-97 (Fig 3B). It is worth mentioning that by IFI, an apparent higher
CD-MPR signal was observed in MCF-7 cells. The latter finding is in line with the higher
expression observed by immunoblotting (Fig 1B).
CD-MPR and CI-MPR display a differential distribution in MCF-7 cells
The CD-MPR and CI-MPR co-exist in most mammalian cells; however, the biological signifi-
cance for such co-existence is still unknown. Although the CI-MPR has already been studied
in MCF-7 cells, no comparative studies have been performed between both MPRs in this cell
line. Therefore, we analysed the distribution of the CI-MPR and compared it with that of
CD-MPR in the MCF-7 cell line. As observed in Fig 4B, CI-MPR showed a dispersed cyto-
plasmic distribution with a signal appearing in the cell periphery, suggesting its presence in the
plasma membrane, in contrast with the perinuclear CD-MPR distribution (Figs 3A and 4A).
Fig 2. Cathepsin D distribution in non-tumorigenic and tumorigenic human breast cell lines. (A) Representative
CatD location in MCF-10A, MCF-7 and MDA-MB-231 cell lines. (B) Co-localization of CatD and LAMP 1 in the
MCF-10A and MCF-7 breast cell lines. (C) Quantitation of co-localization of CatD and LAMP1 (MCC-M1); and
LAMP1 and CatD (MCC-M2) in MCF-10A and MCF-7 cell lines. Values are expressed as the means of Manders co-
localization coefficients 1 and 2 (MCC-M1 and MCC-M2, respectively) ± SEM. () significant difference from MCF-
10A (p<0.05). Scale bar = 20μm.
https://doi.org/10.1371/journal.pone.0201844.g002
CD-MPR and estradiol in MCF-7 cells
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Moreover, only 10% of CI-MPR co-localized with golgin-97, indicating a major location out-
side the Golgi stacks for this receptor.
On the other hand, unlike MCF-7 cells, in the non-tumorigenic MCF-10A cells, both
CD-MPR and CI-MPR showed a more concentrated perinuclear localization with high co-
localization with golgin-97 (Fig 5).
Estradiol regulates the expression and distribution of CatD and CD-MPR
in MCF-7 cells
Taking into account that CatD and CD-MPR are highly expressed in the tumorigenic MCF-7
cells, and that an estrogen response element is present in the CatD gene, we evaluated the effect
of 17-β-estradiol on CatD and CD-MPR expression and distribution on this estrogen-respon-
sive cell line.
It was observed that 17-β-estradiol induces an increase in CatD and CD-MPR expression
(Fig 6A and 6B) at 12, 24 and 48 h of incubation with the hormone, and this effect was blocked
Fig 3. CD-MPR distribution in non-tumorigenic and tumorigenic human breast cell lines. (A) Representative
immunofluorescence staining of CD-MPR and golgin-97 in MCF-10A, MCF-7 and MDA-MB-231 cell lines. Golgin-
97 was used as a TGN marker. (B) Quantification of co-localization of CD-MPR and golgin-97 (MCC-M1); and
golgin-97 and CD-MPR (MCC-M2). Values are expressed as the means of Manders co-localization coefficients 1 and
2 ± SEM. () significant differences from the other cell lines (p <0.001). Scale bar = 25 μm.
https://doi.org/10.1371/journal.pone.0201844.g003
CD-MPR and estradiol in MCF-7 cells
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by the antiestrogen drug tamoxifen. The increment of both proteins was also observed by IFI
(Fig 7B and 7D). In addition, 17-β-estradiol induced a redistribution of CatD and CD-MPR
to the cell periphery (Fig 7A and 7C, respectively). The latter effect was also blocked by
tamoxifen.
A similar experiment was carried out with the non-tumorigenic MCF-10A cells, which lack
the ERα. No significant changes in CatD and CD-MPR expression were observed after treat-
ment with the hormone (Fig 8). These findings support the idea that the changes observed in
MCF-7 cells were mediated by ERα.
Estradiol induces the redistribution of CatD and CD-MPR towards
common compartments
By IFI, we observed that 80% of CatD co-localizes with CD-MPR (MCC-M1: 0.81 ± 0.06) and
that 95% of the CD-MPR co-localizes with CatD (MCC-M2: 0.95 ± 0.05) in control MCF-7
cells. After treatment with estradiol for 24 h, both proteins redistributed partially from a
mostly perinuclear location to a more peripheral granular location, maintaining the high co-
localization rates (Fig 9B). This result suggests that both proteins could share intracellular
compartments, either as free or complexed forms, and that they relocate together under estra-
diol stimulation. This effect was blocked by tamoxifen (Fig 9B).
Fig 4. CD-MPR and CI-MPR co-localization analysis in the MCF-7 tumorigenic cell line. Representative
immunofluorescence staining of (A) CD-MPR and golgin-97 and (B) CI-MPR and golgin-97 in MCF-7 cells. (C)
Quantitative co-localization analysis showing the proportion of CD-MPR that overlaps with golgin-97 (Manders
coefficient 1 –MCC-M1) and the proportion of golgin-97 that overlaps with CD-MPR (MCC-M2). A similar analysis
was done for the CI-MPR. Values are expressed as the means of Manders co-localization coefficient 1 ± SEM. ()
significant difference (p<0.001). Scale bar = 25 μm.
https://doi.org/10.1371/journal.pone.0201844.g004
CD-MPR and estradiol in MCF-7 cells
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To further confirm that the re-distribution of CD-MPR to the plasma membrane was
driven by estradiol, we performed a subcellular fractionation by a discontinuous sucrose gradi-
ent (Fig 10). We observed that estradiol induced the appearance of CD-MPR in low density
fractions enriched in plasma membrane markers [29]. Again, the stimulation with estradiol
induced an increase in the CD-MPR expression. Both effects were also blocked by tamoxifen.
Discussion
In cancer cells, CatD trafficking is altered, and this phenomenon leads to an increase in the
pro-enzyme secretion [30, 31, 32]. Several mechanisms can be proposed to explain the
Fig 5. Immunofluorescence of CD-MPR and CI-MPR in the non-tumorigenic MCF-10A cell line and co-
localization with golgin-97. (A) Representative immunofluorescence staining of CD-MPR and golgin-97 and (B)
CI-MPR and golgin-97 in MCF-10A cells. Cell borders are delimited by a white line. Scale bar = 25 μm.
https://doi.org/10.1371/journal.pone.0201844.g005
Fig 6. Effect of 17-β-estradiol on CatD and CD-MPR expression in MCF-7 cells. Cells were cultured for 12, 24 or 48
h in the absence (control) or in the presence of 20 nM estradiol (EST) or 20 nM EST with 2 μM tamoxifen (EST+Tx).
Representative immunoblots of CatD (A) and CD-MPR (B) from cell lysates at the different timepoints and the
corresponding band intensity quantitation by densitometry (bars graphics). Values are expressed as the means of
relative optical density (R.O.D.) from three independent experiments ± SEM. () significant difference from the other
conditions (p <0.05). Detection of β-tubulin was used as loading control.
https://doi.org/10.1371/journal.pone.0201844.g006
CD-MPR and estradiol in MCF-7 cells
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magnitude of such secretion; e.g., the excessive expression would cause the enzyme to be
secreted to the medium, a detour from the route to lysosomes or a selective transport to the
extracellular medium, among others. In most cell types, acid hydrolases, including CatD, are
delivered to lysosomes by mannose-6-phosphate receptors (MPRs). The present study shows
that MCF-7 cells have higher levels of CD-MPR than other breast-derived cell lines (MCF-10A
and MDA-MB-231), while showing the lowest levels of CI-MPR. This phenomenon would
indicate that both receptors are alternative for the trafficking of mannose-6-phosphate bearing
enzymes [33], and that, in these cell lines, their expression is cross-regulated. Although this
hypothesis is in agreement with that proposed by other authors, it does not fully explain the
fact that both receptors recognize different enzyme sets [34]. Even though in this study we do
Fig 7. Effect of 17-β-estradiol on CatD and CD-MPR expression and distribution in MCF-7 cells. Cells were
cultured for 24 or 48 h in the absence or in the presence of 20 nM estradiol (EST) or 20 nM EST with 2 μM tamoxifen
(EST+Tx). Representative distribution patterns of CatD (A) and CD-MPR (B) and the fluorescence intensity
quantitation, (C) and (D), respectively. Values are expressed as the means of relative fluorescence units (R.F.U.) ± SEM
from 60 cells counted at each condition. () significant difference (p<0.001). Scale bar = 20 μm.
https://doi.org/10.1371/journal.pone.0201844.g007
Fig 8. CatD and CD-MPR expression in MCF-10A human breast cells after treatment with 17-β-estradiol. MCF-
10A cells were cultured for 48 h in the absence (control) or in the presence of 20 nM estradiol (EST) or 20 nM EST
with 2 μM tamoxifen (EST+Tx). Representative immunoblots of CatD (A) and CD-MPR (B) from cell lysates and the
corresponding band intensity quantitation by densitometry. Bars represent the means of relative optical densities (R.O.
D.) from two independent experiments ± SEM. Ponceau staining was used as loading control.
https://doi.org/10.1371/journal.pone.0201844.g008
CD-MPR and estradiol in MCF-7 cells
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not present direct supporting evidence, the increased simultaneous expression of CD-MPR
and CatD in MCF-7 cells would suggest that CD-MPR is a receptor for this enzyme. However,
Fig 9. Co-localization analysis between CatD and CD-MPR in MCF-7 breast cancer cells. Representative IFI for the
detection of CD-MPR (a) and CatD (b) in MCF-7 cells, control (A), treated with 20 nM EST (B) or treated with 20 nM
EST+ 2 μM Tx (C). (c) Merged Images; (d) Scatter plot of co-localization events for CD-MPR and CatD; and (e) Cross-
correlation function: PCCs vs. pixel shift (δx) for each case. (a´b´c´) amplifications of the areas limited by rectangles.
PCC values: controls = 0.708 ± 0.04, EST = 0.776 ± 0.03, EST+Tx = 0.792 ± 0.05. Images are representative of three
independent experiments.
https://doi.org/10.1371/journal.pone.0201844.g009
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the role of sortilin in cathepsin D transport in breast cancer cells should not be ruled out, since
this receptor in known to participate in the sorting of lysosomal proteins including cathepsin
D in other cell types [12, 13]. It has been documented that sortilin can mediate cathepsin D
delivery to lysosomes when the MPR pathway is impaired [12]. Exploring the role of sortilin in
intracellular transport in breast cancer cells could prove to be of substantial interest for future
studies.
By IFI, we observed that CatD is mostly located perinuclearly, and also dispersed in the
cytoplasm. However, it is noteworthy that the enzyme is also located at the periphery of the
tumorigenic (MCF-7), but not in the non-tumorigenic cells. In tumorigenic cells, the presence
of CatD in the cell periphery could be attributed to vesicle accumulation for eventual secretion.
In fact, about 36% of the total intracellular CatD is present in LAMP1-negative compartments
in MCF-7 cells.
Apart from the differences observed in the expression of the MPRs, we have also observed
that both, CD-MPR and CI-MPR, are distributed differently in MCF-7 cells; while CD-MPR is
mostly concentrated in the Golgi stacks and likely in endosomal compartments, the CI-MPR
is more dispersed throughout the cytoplasm and also at the cell periphery. In addition, the
high degree of co-localization coefficient of the CD-MPR with golgin-97 confirms that this
receptor is mostly located in the Golgi stacks, as compared to the CI-MPR. The atypical gol-
gin-97 dispersed distribution in MCF-7 cells was consistent with the presence of a fragmented
Golgi apparatus already described in these cells [35]. The perinuclear CD-MPR distribution is
common in most mammalian cell types [36], while the additional dispersed signal appears to
be a feature of tumorigenic MCF-7 cells. The different distribution of the two MPRs in MCF-7
Fig 10. Effect of 17-β-estradiol on the distribution of CD-MPR in MCF-7 breast cancer cells. Cells were cultured in
the presence of 20 nM estradiol (EST) or 20 nM EST with 2 μM tamoxifen (EST+Tx) for 24 h, and subsequently, cell
lysates were loaded on sucrose gradients. Gradient fractions were analyzed by immunoblotting. (A) Detection of
CD-MPR. (B) Percentage distribution quantitation obtained by densitometric analysis of each fraction. (C) Fraction
densities estimated from weight/volume ratios.
https://doi.org/10.1371/journal.pone.0201844.g010
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cells is consistent with the idea that both proteins are not redundant but complementary [26].
On the other hand, the CI-MPR has been proposed as a tumor suppressor molecule whose
expression is downregulated by estradiol [21, 37, 38]. Unlike CI-MPR, in this work we have
observed that the expression of CD-MPR is significantly increased by the action of estrogen in
MCF-7 cells, and that this effect is blocked by the antiestrogenic drug tamoxifen. Moreover,
this effect was accompanied by an increase of CatD levels. It is noteworthy that this is the first
study suggesting an estradiol-driven regulation of CD-MPR. The fact that estradiol did not
induce changes in MCF-10A cells indicates that the hormonal effect on MCF-7 cells is medi-
ated by ERα. Moreover, this hypothesis is supported by the blocking effect of tamoxifen
observed in MCF-7 cells. The results obtained in other models indicate that CD-MPR expres-
sion and distribution can be modulated by testosterone [39, 40]. Whether the high levels of
CD-MPR found upon estradiol stimulation are due to an increased synthesis or a diminished
degradation of the receptor remains to be determined. Since the CD-MPR-encoding gene does
not have hormone responsive elements, it may be possible that the levels of this receptor were
regulated indirectly through the CatD response to the hormone. In fact, it has been reported
that CatD can localize to the nucleus of cancer cells, where it could participate in transcription
regulation by cleaving and/or interacting with nuclear proteins, thus modulating their activity
[41, 42]. As in other physiological models [26], the possibility of a cross-regulation of the
expression of CD-MPR and CI-MPR cannot be ruled out.
Taking into account the results obtained herein, it is of interest to elucidate the role of
CD-MPR in tumor cells, and whether there exists a direct link between CD-MPR and CatD.
Although CD-MPR has scarcely been explored in cancer models, some authors have proposed
a pro-tumorigenic role for this receptor [43]. It is hypothesized that the CD-MPR is a receptor
for CatD, which participates in the enzyme secretion by cancer cells. In this regard, we
observed high co-localization levels of the two proteins, both in the perinuclear region and
adjacent to the plasma membrane. In addition, estradiol induced a redistribution of both pro-
teins to the adjacency of the cell membrane, maintaining that high co-localization. The redis-
tribution of the enzyme induced by the hormone is consistent with the estradiol-induced-
secretion reported in the literature [6, 2]. Moreover, we confirmed the estradiol-induced
CD-MPR redistribution when the receptor localized to low density fractions of the discontinu-
ous sucrose gradient. These observations are supported by a previous work performed in
another model in which the redistribution of CD-MPR towards the plasma membrane was
found to correlate with high CatD secretion rates [39]. Moreover, Chao et al. have suggested a
role for CD-MPR in selective enzyme secretion [20].
To sum up, we suggest that the CD-MPR would be selectively re-routed together with man-
nose-6-phosphate ligands (e.g. cathepsins) towards the plasma membrane by some mechanism
that involves recognition signals in the CD-MPR cytoplasmic domain, which are different
from those motifs that are known to participate in other intracellular transport routes [44].
Subsequently, the acidic pH of the tumor microenvironment [45] would favor the ligand-
receptor complex dissociation and release of the enzyme to the extracellular medium.
In conclusion, our results provide new insights to clarify the mechanism by which human
breast tumor cells distribute and secrete high amounts of proteases. This process would involve
a receptor-mediated selective transport regulated by estradiol. Interfering with these processes
would be a new strategy for future therapies against breast cancer.
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S1 Fig. Supporting images for Fig 1. (A) and (B) Representative immunoblottings of cathep-
sin D with their respective loading controls. The fourth line in (B) shows MCF-7 proteins
loaded at lesser concentration. (C) and (D) Representative immunoblotting of CD-MPR with
their respective loading controls. Liver proteins were used as detection control for CD-MPR.
(E) Representative immunoblotting of CI-MPR with its respective loading control. (B), (D)
and (E) show the molecular size markers (GeneDirex Cat. PM005-0500S and Cat. PM008-
0500S).
(TIF)
S2 Fig. Supporting images for Fig 6. (A) Representative immunoblotting of cathepsin D with
its respective loading control and the membrane showing nonspecific secondary antibody
binding. (B) Representative immunoblotting of CD-MPR with its respective loading control
and the membrane showing nonspecific secondary antibody binding. Alb Biot: Biotinylated
bovine serum albumin used as detection control.
(TIF)
S3 Fig. Supporting images for Fig 8. Immunoblottings of cathepsin D and CD-MPR with
respective loading control showing the molecular size marker.
(TIF)
S4 Fig. Supporting images for Fig 10. Immunoblottings of CD-MPR from the sucrose gradi-
ent fractions.
(TIF)
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